Regulus Therapeutics Inc.
RGLS
株式のランク
#17341
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
株価
$8.16
最終同期: 2025-06-26
時価総額
$234.57M
変化（1日）
0.00%
変化（1年）
-56.96%
国
US
取引 Regulus Therapeutics Inc. (RGLS)
カテゴリー
Healthcare
Regulus Therapeutics Inc.（RGLS）の営業利益率
October 2026 時点の営業利益率 TTM: -105.96%
Regulus Therapeutics Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は -105.96% です。2022 年末時点では 58.31% でした。
Regulus Therapeutics Inc. の営業利益率の履歴（2002 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | -105.96% | 0.00% |
| 2023 | -105.96% | -281.72% |
| 2022 | 58.31% | -137.72% |
| 2021 | -154.57% | -524.18% |
| 2020 | 36.44% | -124.87% |
| 2019 | -146.50% | 86.93% |
| 2018 | -78.37% | -21.93% |
| 2017 | -100.39% | -14.99% |
| 2016 | -118.09% | -744.24% |
| 2015 | 18.33% | -337.74% |
| 2014 | -7.71% | -156.28% |
| 2013 | 13.70% | 174.55% |
| 2012 | 4.99% | -56.11% |
| 2011 | 11.37% | 0.44% |
| 2010 | 11.32% | -19.55% |
| 2009 | 14.07% | -38.61% |
| 2008 | 22.92% | 102.29% |
| 2007 | 11.33% | -2.75% |
| 2006 | 11.65% | -84.91% |
| 2005 | 77.21% | 2,544.18% |
| 2004 | 2.92% | -112.90% |
| 2003 | -22.64% | -85.13% |
| 2002 | -152.28% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -100.36% |
US
|
|
| -149.01% | -98.59% |
US
|
|
| 25.57% | -100.24% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.27% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。